{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:31:12Z","timestamp":1792755072733,"version":"4.5.0"},"reference-count":6,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2020,2,1]]},"DOI":"10.1001\/jamaoncol.2019.5426","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T16:31:17Z","timestamp":1576168277000},"page":"296","source":"Crossref","is-referenced-by-count":14,"title":["Use of Bone-Modifying Agents Among Medicare Beneficiaries With Multiple Myeloma"],"prefix":"10.1001","volume":"6","author":[{"given":"Arjun","family":"Gupta","sequence":"first","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Abbas","family":"Ali","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bishal","family":"Gyawali","sequence":"additional","affiliation":[{"name":"Division of Cancer Care and Epidemiology, Department of Oncology, Queen's University, Kingston, Ontario, Canada"},{"name":"Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi N.","family":"Overton","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland"},{"name":"Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A.","family":"Makary","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland"},{"name":"Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"cld190025r1","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"key":"cld190025r2","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.1598","article-title":"Denosumab vs zoledronic acid for bone-targeted therapy in multiple myeloma: what are the unanswered questions?","author":"Chakraborty","year":"2019","journal-title":"JAMA Oncol"},{"key":"cld190025r3","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.3853","article-title":"Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment: a prospective 2-year clinical trial.","author":"Anastasilakis","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"9","key":"cld190025r4","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1200\/JCO.2010.33.5596","article-title":"Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: incremental benefit, debatable value.","volume":"29","author":"West","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"cld190025r5","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3324\/haematol.2017.185264","article-title":"Denosumab for bone lesions in multiple myeloma: what is its value?","volume":"103","author":"Goldstein","year":"2018","journal-title":"Haematologica"},{"issue":"8","key":"cld190025r6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.9570","article-title":"Assessing the justification, funding, success, and survival outcomes of randomized noninferiority trials of cancer drugs: a systematic review and pooled analysis.","volume":"2","author":"Gyawali","year":"2019","journal-title":"JAMA Netw Open"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2757382\/jamaoncology_gupta_2019_ld_190025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T16:01:12Z","timestamp":1581609672000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2757382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,1]]},"references-count":6,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2019.5426","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,1]]}}}